This research, published in the Genes & Diseases journal by a team from Fujian Medical University and Sun Yat-Sen University, conducted a comprehensive bioinformatic and clinical analysis to examine the pan-cancer association between ALK mutation, tumour immunity, and ICB efficacy.

By analysing clinical data from 2,930 patients across 11 different tumour types treated with immune checkpoint inhibitors, researchers discovered that the presence of ALK mutations is an independent favourable predictor of overall survival.

Specifically, ALK mutations decreased the risk of patient death by 31%.

Based on these robust findings, the team developed and validated a nomogram to successfully estimate 12-month and 24-month survival probabilities for patients following the initiation of immunotherapy.

Multi-omics analyses further revealed that ALK-mutant tumours exhibit significantly heightened intrinsic immunity, characterised by a higher tumour mutation burden (TMB) and an increase in both non-silent and silent mutation rates.

Moreover, the study deciphered the underlying extrinsic immune mechanisms driven by ALK mutations.

Compared to non-mutant tumours, ALK-mutant tumours demonstrated a heavily enriched infiltration of immune cells, higher abundances of neoantigens, and greater T-cell and B-cell receptor (TCR/BCR) diversity.

Crucially, the mRNA expression levels of major immune checkpoints, including CTLA-4, PD-1, and PD-L1, alongside various immune-stimulators and chemokines, were significantly upregulated in ALK-mutant tumours.

Remarkably, these findings demonstrate that ALK-mutant tumours function as immunologically "hot" tumours, uniquely primed for robust responses to immune checkpoint inhibitors.

While these collective data highlight the crucial role of ALK mutations in shaping a favourable systemic and local immune landscape, additional prospective trials are needed to fully validate these results and explore optimal immunotherapy combination strategies.

In conclusion, treating ALK mutation as a pan-cancer biomarker offers a powerful new strategy to identify patients who will benefit most from immune checkpoint blockade.

This profound finding positions ALK mutation screening as an essential tool for personalised clinical decision-making and the development of next-generation cancer immunotherapies.

Source: Compuscript Ltd